LinkedIn Profile

Access Stabilitech historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:stabilitech 1828957 Jun 1st, 2019 12:00AM Stabilitech Biopharma Ltd 104 11.00 Open Biotechnology Jun 1st, 2019 02:30AM Jun 1st, 2019 02:30AM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Open vaccine stability, oral gene therapy platform, biologic stability, influenza vaccine, Zika vaccine, cold chain enhancement, oral viral vectored proteins, thermostability Open GB Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Mar 26th, 2018 12:00AM Stabilitech Biopharma Ltd 80 11.00 Open Biotechnology Mar 26th, 2018 05:36PM Mar 26th, 2018 05:36PM Open Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Feb 17th, 2018 12:00AM Stabilitech Biopharma Ltd 73 11.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Feb 16th, 2018 12:00AM Stabilitech Biopharma Ltd 73 11.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Feb 15th, 2018 12:00AM Stabilitech Biopharma Ltd 73 11.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Feb 14th, 2018 12:00AM Stabilitech Biopharma Ltd 73 11.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Feb 13th, 2018 12:00AM Stabilitech Biopharma Ltd 73 11.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Feb 12th, 2018 12:00AM Stabilitech Biopharma Ltd 73 11.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Feb 11th, 2018 12:00AM Stabilitech Biopharma Ltd 73 11.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Pharmaceuticals & Biotechnology
private:stabilitech 1828957 Feb 10th, 2018 12:00AM Stabilitech Biopharma Ltd 73 11.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system. Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.